Romosozumab or alendronate for fracture prevention in women with osteoporosis

New England Journal of Medicine

Volumn 377, Issue 15, 2017, Pages 1417-1427

  Saag, Kenneth G ^a   Petersen, Jeffrey ^b   Brandi, Maria Luisa ^c   Karaplis, Andrew C ^d   Lorentzon, Mattias ^e   Thomas, Thierry ^f   Maddox, Judy ^b   Fan, Michelle ^b   Meisner, Paul D ^g   Grauer, Andreas ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF FLORENCE   (Italy)

^d MCGILL UNIVERSITY   (Canada)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^g UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ROMOSOZUMAB; BONE DENSITY CONSERVATION AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BACKACHE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; FEMALE; FEMUR FRACTURE; FRAGILITY FRACTURE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HIP FRACTURE; HUMAN; HYPEROSTOSIS; HYPOCALCEMIA; INJECTION SITE REACTION; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASM; MULTICENTER STUDY; OSTEOARTHRITIS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK REDUCTION; SPINE FRACTURE; TREATMENT DURATION; BONE DENSITY; BONE REMODELING; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG EFFECTS; FRACTURES, BONE; INCIDENCE; LEAST SQUARE ANALYSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK; SPINAL FRACTURES;

AGED; ALENDRONATE; ANTIBODIES, MONOCLONAL; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FRACTURES, BONE; HUMANS; INCIDENCE; LEAST-SQUARES ANALYSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK; SPINAL FRACTURES;

EID: 85031030988     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1708322     Document Type: Article

References (32)

1. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7.
2. Kanis JA, Hans D, Cooper C, et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int 2011;22:2395-411.
3. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014;370:412-20.
4. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26.
5. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016;375:1532-43.
6. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
7. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
8. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.
9. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65.
10. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348:1535-41.
11. Kendler D. Effects of 24 months treatment of teriparatide compared with risedronate on new fractures in postmenopausal women with severe osteoporosis: a randomized, double-dummy clinical trial (VERO trial). Presented at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Florence, Italy, March 23–26, 2017.
12. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2.
13. Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23: 508-16.
14. Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005; 16:468-74.
15. Keaveny TM, Crittenden DB, Bolognese MA, et al. Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass. J Bone Miner Res 2017;32:1956-62.
16. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001;68:577-89.
17. Chouinard L, Felx M, Mellal N, et al. Carcinogenicity risk assessment of romosozumab: a review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study. Regul Toxicol Phar-macol 2016;81:212-22.
18. Didangelos A, Yin X, Mandal K, Baumert M, Jahangiri M, Mayr M. Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics 2010;9:2048-62.
19. Brandenburg VM, Kramann R, Koos R, et al. Relationship between sclerostin and cardiovascular calcification in hemodialy-sis patients: a cross-sectional study. BMC Nephrol 2013;4219.
20. Kramann R, Kunter U, Brandenburg VM, et al. Osteogenesis of heterotopically transplanted mesenchymal stromal cells in rat models of chronic kidney disease. J Bone Miner Res 2013;28:2523-34.
21. Rukov JL, Gravesen E, Mace ML, et al. Effect of chronic uremia on the transcriptional profile of the calcified aorta analyzed by RNA sequencing. Am J Physiol Renal Physiol 2016;310:F477-F491.
22. Zhu D, Mackenzie NC, Millán JL, Farquharson C, MacRae VE. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 2011;6(5): e19595.
23. Claes KJ, Viaene L, Heye S, Meijers B, d’Haese P, Evenepoel P. Sclerostin: another vascular calcification inhibitor? J Clin En-docrinol Metab 2013;98:3221-8.
24. Ominsky MS, Boyd SK, Varela A, et al. Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys. J Bone Miner Res 2017;32:788-801.
25. Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. Clin Genet 2003;63:192-7.
26. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008; 23:860-9.
27. van Buchem F, Prick J, Jaspar H. Hyperostosis corticalis generalisata familiaris (van Buchem’s disease). In: Excerpta med-ica. New York: Elsevier, 1976:1-205.
28. Vanhoenacker FM, Balemans W, Tan GJ, et al. Van Buchem disease: lifetime evolution of radioclinical features. Skeletal Radiol 2003;32:708-18.
29. Kang JH, Keller JJ, Lin HC. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int 2013;24:271-7.
30. Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC. Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One 2015;10(4): e0122646.
31. Kranenburg G, Bartstra JW, Weijmans M, et al. Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis. Atherosclerosis 2016; 52:106-15.
32. Lu PY, Hsieh CF, Tsai YW, Huang WF. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. Clin Ther 2011;33:1173-9.